Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 15 Jul 2022
TGA approves Grifols' Xembify
15 July 2022 - Xembify is yet another presentation of human immunoglobulin. ...
Posted by Michael Wonder on 15 Jul 2022
Chief Medical Officer’s statement on standard of care on COVID-19 oral antiviral treatments in residential aged care facilities
15 July 2022 - A statement from Professor Paul Kelly, Australian Government Chief Medical Officer, about the standard of care on ...
Posted by Michael Wonder on 14 Jul 2022
Marinus Pharmaceuticals sells rare paediatric disease priority review voucher for $110 million
14 July 2022 - Marinus Pharmaceuticals today announced that it has entered into a definitive agreement to sell its rare ...
Posted by Michael Wonder on 14 Jul 2022
Breakthrough treatment to boost life chances for hundreds of people with respiratory cancer
14 July 2022 - The first new mesothelioma treatment to be approved in nearly 15 years will be made available ...
Posted by Michael Wonder on 14 Jul 2022
FDA clears DyAnsys neurostimulation device first relief to treat diabetic neuropathic pain
14 July 2022 - First Relief, a PENS (percutaneous electrical neurostimulation) device, has been cleared by the US FDA for ...
Posted by Michael Wonder on 14 Jul 2022
Thousands of patients to benefit as NHS marks 100th fast tracked cancer drug
14 July 2022 - Thousands of people a year with advanced breast cancer will benefit from a life extending drug ...
Posted by Michael Wonder on 14 Jul 2022
FDA approves crizotinib for ALK positive inflammatory myofibroblastic tumour
14 July 2022 - On 14 July 2022, the FDA approved crizotinib (Xalkori, Pfizer) for adult and paediatric patients one ...
Posted by Michael Wonder on 14 Jul 2022
COVID-19 vaccine safety report (14 July 2022)
14 July 2022 - To 10 July 2022, the TGA has received 609 reports which have been assessed as likely to ...
Posted by Michael Wonder on 14 Jul 2022
Roxadustat for treating symptomatic anaemia in chronic kidney disease
13 July 2022 - NICE has published evidence-based recommendations on the use of roxadustat (Evrenzo) for the treatment of adults ...
Posted by Michael Wonder on 14 Jul 2022
Revolo Biotherapeutics awarded Innovation Passport for ‘1805 in the United Kingdom for the treatment of moderate to severe rheumatoid arthritis
14 July 2022 - Revolo Biotherapeutics today announced that it was awarded an Innovative Medicines Designation, or Innovation Passport, from the ...
Posted by Michael Wonder on 14 Jul 2022
BeiGene provides regulatory update on the U.S. biologics license application for PD-1 inhibitor tislelizumab in second-line oesophageal squamous cell carcinoma
14 July 2022 - Due to COVID travel restrictions, inspections could not be completed during review period. ...
Posted by Michael Wonder on 14 Jul 2022
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018
14 July 2022 - An agreement with the companies on the price of two breast cancer treatments, Piqray and Trodelvy, has ...
Posted by Michael Wonder on 14 Jul 2022
Zai Lab announces acceptance by China’s NMPA of the BLA for efgartigimod for patients with generalised myasthenia gravis
13 July 2022 - Efgartigimod alfa injection is the first accepted BLA submission of an FcRn antagonist for generalised myasthenia gravis ...
Posted by Michael Wonder on 14 Jul 2022
PHARMAC widens access for COVID-19 anti-viral treatments
14 July 2022 - Pharmac has confirmed today that it is further widening access to the three anti-viral treatments it ...
Posted by Michael Wonder on 14 Jul 2022
FDA grants Alpheus Medical orphan drug and fast track designations for novel sonodynamic therapy for brain cancer
13 July 2022 - The company is currently enrolling patients in a multicentre Phase 1 clinical trial for the treatment ...